Is plasma microRNA-21 a potential diagnostic biomarker of acute myocardial infarction?
Plasma miR-21 may be a novel biomarker for the diagnosis of AMI. Our study may also provide implications for the development of new biomarkers.
Standard-dose statin therapy provides incremental clinical benefits in DM patients with normal cholesterol levels compared with non-DM patients. The data suggest that DM patients may enjoy the pleiotropic effects of statins, independent of the LDL-cholesterol lowering effects of these agents.